共 40 条
[2]
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
[J].
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,
2017, 76 (03)
:405-417
[3]
Brunasso AMG, 2022, J DRUGS DERMATOL, V21, P914, DOI [10.361349/JDD.6828, 10.36849/JDD.6828]
[4]
Burlando Martina, 2021, Drugs Context, V10, DOI 10.7573/dic.2021-2-6
[6]
European Medicines Agency, 2018, ASS REP ILUM INT NON